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Introduction
Adenovirus types 4 and 7 (Ad4 and Ad7) are the primary 
causative infectious agents in acute respiratory distress (ARD) 
in military recruits during basic training.1 Typically, Ad-ARD 
is associated with fever, rhinorrhea, pharyngitis, headache, and 
lethargy that is self-limiting and usually resolved in 3 to 10 d. 
While Ad-ARD rarely results in death and about 10% of patients 
develop pneumonia, the major impact of Ad-ARD is the loss of 
training time. Ad-ARD spreads rapidly and has been shown to 
affect up to 80% of recruits within a confined military training 
facility resulting in 20% of patients requiring hospitalization.2-4 
Since 1971, millions of military recruits have been vaccinated 
against Ad4 and Ad7 using an orally delivered lyophilized wild-
type virus.5 This vaccine has been found to be safe and effective.6,7 
The vaccine used by the military was so effective at reducing the 
rates of respiratory febrile illness that officials opted to suspend 
the vaccine program. Once the vaccine program was halted, cases 
of Ad4 and Ad7 associated respiratory illnesses began to increase 
and, in 2001, efforts to restore the vaccine program were initi-
ated. Over the past 10 y, the US military has invested ~$100 
million to fully restore vaccine production and vaccination of 
military recruits in 2011.7 Ad-ARD cases declined rapidly upon 
the restoration of this vaccine program.
Adenovirus Type 5 (Ad5) has been shown to be a very effec-
tive viral vector for use in vaccine studies.8-13 However, There are 
very high levels of pre-existing immunity to Ad5 in all popu-
lations.14-16 In many populations the pre-existing immunity is 
100% by the age of 2.14 Therefore, Ad5 seroprevalence is a fun-
damental problem that is inhibitory to the use of Ad5 as a vaccine 
vector in adult humans. A study of 303 military basic trainees 
indicated that Ad4 and Ad7 levels of seroprevalence were 34% 
and 27%, respectively. Therefore, 89% of these recruits would 
be susceptible to vaccination with at least 1 of the 2 Ad4 or Ad7 
vaccines.17 Ad4 and Ad7 have been studied as vaccine vectors for 
several infectious diseases such as HIV, Hepatitis B, respiratory 
syncytial virus (RSV) and, most recently, bird flu (H5N1).6,18-22 
As Ad4 and Ad7 are the only 2 adenoviruses ever used as vaccines 
in humans to prevent Ad4 and Ad7 ARD, they are very attrac-
tive as vaccine vectors for the inclusion of secondary pathogen 
genes. Military recruits are vaccinated or boosted against sev-
eral other pathogens with traditional vaccines.23 However, some 
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adenovirus Types 4 and 7 (ad4 and ad7) are associated with acute respiratory distress (aRD). In order to prevent wide-
spread ad-associated aRD (ad-aRD) the United states military immunizes new recruits using a safe and effective lyophi-
lized wildtype ad4 and ad7 delivered orally in an enteric-coated capsule. We cloned ad4 and ad7 and modified them 
to express either a GFP-Luciferase (GFPLuc) fusion gene or a centralized influenza H1 hemagglutinin (Ha1-con). BaLB/c 
mice were injected with GFPLuc expressing viruses intramuscularly (i.m.) and intranasally (i.n.). ad4 induced significantly 
higher luciferase expression levels as compared with ad7 by both routes. ad7 transduction was restored using a human 
cD46+ transgenic mouse model. Mice immunized with serial dilutions of viruses expressing the Ha1-con influenza vac-
cine gene were challenged with 100 MLD50 of influenza virus. ad4 protected BaLB/c mice at a lower dose by i.m. immu-
nization as compared with ad7. Unexpectedly, there was no difference in protection by i.n. immunization. although ad7 
i.m. transduction was restored in cD46+ transgenic mice, protection against influenza challenge required even higher 
doses as compared with the BaLB/c mice. However, ad7 i.n. immunized cD46+ transgenic mice were better protected as 
compared with ad4. Interestingly, the restoration of ad7 transduction in cD46+ mice did not increase vaccine efficacy 
and indicates that ad7 may transduce a different subset of cells through alternative receptors in the absence of cD46. 
These data indicate that both ad4 and ad7 can effectively induce anti-H1N1 immunity against a heterologous challenge 
using a centralized H1 gene. Future studies in non-human primates or human clinical trials will determine the overall 
effectiveness of ad4 and ad7 as vaccines for influenza.
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recruits will be vaccinated against pathogens such as smallpox 
and anthrax. Vaccines for these pathogens are considered danger-
ous or require multiple immunizations with annual boosters.23 In 
this study we show that these viral vectors are capable of induc-
ing anti-H1N1 influenza immune responses. We hope that these 
data, in combination with vaccine studies from other groups, will 
result in the design of a multivalent vaccine platform.
Results
In vivo transduction of viral vectors
BALB/c mice were immunized with Ad4 and Ad7 viral vec-
tors expressing the GFPLuc gene and imaged 24 h. later. By 
intramuscular immunization, the Ad4 viral vector induced sig-
nificantly higher levels of luciferase activity as compared with the 
Ad7 viral vector (P = 0.02) (Fig. 1). By the intranasal route, the 
Ad4 viral vector also induced significantly higher levels of lucif-
erase activity as compared with Ad7 (P = 0.01) (Fig. 1). However, 
when CD46+ transgenic mice were immunized intramuscularly 
with the Ad7 viral vector, luciferase activity was restored to levels 
equivalent to that of Ad4 in BALB/c mice (Fig. 1B and C). A 
commonly used Ad5 replication-defective viral vector was used as 
a comparator. Ad4 and Ad7 also induced higher luciferase levels 
as compared with the Ad5 vector (P = 0.04 and P = 0.06, respec-
tively) (Fig. 1B and C). Interestingly, the Ad4-GFPLuc viral vec-
tor appeared to migrate from the intramuscular injection site to 
the liver as detected by imaging. This may be an indicator of the 
liver tropic properties of adenoviruses that use the coxsackie and 
adenovirus receptor (CAR) for transduction.
Protection by systemic intramuscular immunization in 
BALB/c mice
Groups of 5 female BALB/c mice were immunized intramus-
cularly with serial 10-fold dilutions of Ad4 and Ad7 vaccine vec-
tors expressing a centralized H1 hemagglutinin gene, HA1-con. 
Three weeks post-immunization, the mice were challenged with 
100 MLD
50
 of influenza A/PR/8/34. Mice immunized with Ad4 
at a dose as low as 109 vp/mouse showed reduced disease and 
weight loss (Fig. 2A). Immunization with 109 vp/mouse of Ad4 
vaccine also protected 100% of mice from death due to a lethal 
challenge of influenza virus (Fig. 2B). In contrast, 1010 vp/mouse 
of Ad7 vaccine was required to reduce weight loss in influenza 
virus challenged BALB/c mice (Fig. 2C). Intramuscular vaccina-
tion with Ad7 required a 10-fold higher concentration (1010 vp/
mouse) to completely protect mice from death as compared with 
the Ad4 vaccine (Fig. 2D).
Protection by mucosal intranasal immunization in BALB/c 
mice
Groups of 5 female BALB/c mice were immunized intrana-
sally with serial 10-fold dilutions of Ad4 and Ad7 vaccine vectors 
expressing HA1-con. Three weeks post-immunization, the mice 
were challenged with 100 MLD
50
 of influenza A/PR/8/34. By 
this route and in this mouse model, there were no differences 
in vaccine efficacy by either Ad4 or Ad7 (Fig. 3). However, the 
dose required to completely protect mice from death was 10-fold 
higher by the intranasal route as compared with the intramus-
cular route (Fig. 3A and B). Interestingly, the Ad7 mice immu-
nized with 1010 vp/mouse did not lose any weight and showed no 
signs of disease or death (Fig. 3C and D). In fact, mice immu-
nized with this dose by the i.m. route showed > 10% weight loss, 
whereas, mice immunized i.n. showed an overall weight gain over 
the 2 wk after influenza challenge (Fig. 3C).
Protection by systemic intramuscular immunization in 
CD46+ transgenic mice
Since CD46 appeared to restore Ad7 transduction, we immu-
nized groups of 5 female CD46+ transgenic mice intramuscu-
larly with serial 10-fold dilutions of Ad4 and Ad7 vaccine vectors 
expressing HA1-con. The mice were challenged 3 wk post-
immunization with 100 MLD
50
 of influenza A/PR/8/34. In this 
Figure  1. In vivo transduction of ad4 and ad7 vectors. ad4 and ad7 
viruses expressing a GFPLuc fusion gene were used to immunize mice 
by intramuscular and intranasal routes and imaged for luciferase activity 
24 h later. In vivo transduction and luciferase expression in BaLB/c mice 
is shown (A). Intramuscular transduction of ad7 was restored in cD46+ 
transgenic mice and compared with a standard replication-defective 
ad5 vector expressing the same transgene (B). The sum lumenescence 
was determined using the lumazone analysis software and levels were 
compared using a 2-tailed T-Test (C). error bars indicate standard error.
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mouse model, Ad4 was even less effective at protecting mice from 
weight loss (Fig. 4A) and even groups of mice receiving the high-
est dose of 1010 vp/mouse of Ad4 were not completely protected 
from death upon influenza challenge (Fig. 4B). In contrast to the 
in vivo luciferase data, the Ad7 vaccine was even less effective at 
protecting mice from weight loss and death after a lethal influ-
enza challenge (Fig. C and D). Interestingly, the lowest does of 
Ad7 vaccine (108 vp/mouse) resulted in the highest survival rate 
of 60% as compared with 20% for the higher doses (Fig. 4D).
Protection by mucosal intranasal immunization in CD46+ 
transgenic mice
Groups of 5 female CD46+ transgenic mice were immunized 
intranasally with serial 10-fold dilutions of Ad4 and Ad7 vaccine 
vectors expressing HA1-con and challenged 3 wk post-immuni-
zation with 100 MLD
50
 of influenza A/PR/8/34. Ad4 induced 
lower levels of protection by this route as compared with the 
i.m. route. Even the highest i.n. dose of Ad4 vaccine was unable 
to completely protect CD46+ mice from weight loss and death 
(Fig. 5A and B). Vaccination of mice with 1010 vp/mouse of Ad4 
vaccine resulted in only 60% survival (Fig. 5B). Ad7 immunized 
CD46+ mice had a delayed weight loss as compared with the Ad4 
immunized mice (Fig. 5C). However, all doses of Ad7 resulted in 
death after influenza challenge (Fig. 5D). Interestingly, the inter-
mediate (109) and low (108) doses of Ad7 vaccine induced greater 
levels of survival as compared with the Ad4 vaccine.
Discussion
There is a definite need to improve our current vaccine tech-
nologies. Here we report the cloning of Ad4 and Ad7 into single 
low copy plasmids. These plasmids allow for the ability to rap-
idly create and modify the genomes to act as vaccine vectors. We 
deleted the E3 genes of both Ad4 and Ad7 and replaced them 
with CMV-transgene cassettes that expressed either a GFPLuc 
or a centralized H1 hemagglutinin (HA1-con). We then tested 
these viral vectors to transduce BALB/c and CD46+ transgenic 
mice and to induce anti-influenza immunity. While both vec-
tors were capable of inducing protection against a heterologous 
influenza A/PR/8/34 lethal virus challenge, the dose required 
to induce protection was higher than previously observed using 
a replication-defective Ad5 (RD-Ad) vectored vaccine.11 In order 
to determine if the levels of protein expression were equivalent 
in both Ad4 and Ad7 vaccines, we evaluated GFP and lucifer-
ase expression in vitro. We found that Ad4 and Ad7 viruses had 
similar virus particle to infectious unit ratios of 103.6 and 95.1, 
respectively (Fig. S1A). In addition, there were no significant 
differences in luciferase activity expressed by either Ad4 or Ad7 
(Fig. S1B). While these data do not represent the actual vaccine 
gene (HA1-con) expression, they do indicate that, at least in 
the context of these expression cassettes, it may be inferred that 
HA1-con expression levels are equivalent.
Figure 2. Protection by systemic intramuscular immunization in BaLB/c mice. Groups of 5 female BaLB/c mice were immunized intramuscularly with 
10-fold serial dilutions of ad4 or ad7 expressing the centralized Ha1-con hemagglutinin gene. Three weeks after immunization the mice were chal-
lenged with 100 MLD50 of mouse-adapted influenza a/PR/8/34. Protection against weight loss and survival induced by the ad4 vaccine is shown in A and 
B, respectively. Protection against weight loss and survival induced by the ad7 vaccine is shown in C and D, respectively. Mice that lost 25% of baseline 
body weight were humanely euthanized.
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Since the Ad4 and Ad7 viral vaccines were replication-com-
petent (RC-Ad) they may have induced changes to the Th1/Th2 
balance, T-regulatory responses, or inflammatory cytokine pro-
files as compared the RD-Ad vector. The E3 genes play a signifi-
cant role in immunoevasion and immunomodulation during Ad 
infections.24-26 The deletion of the E3 genes without the deletion 
of the E1 genes may have impaired this vector as a vaccine, at 
least in mice. The anti-Ad4 and Ad7 immune responses gener-
ated in the mice by the E3 deleted vectors may have weakened 
the anti-influenza immune responses. Vaccination with RD-Ad4 
and Ad7 viruses may ameliorate this effect. A RD-Ad4 and Ad7 
vector that is delivered to military recruits in a manner similar 
to the FluMist vaccine may induce stronger anti-vector and anti-
transgene immune responses. In addition, studies have shown 
that Ad vectors can be re-administered when delivered intrana-
sally.27-32 Therefore, boosting with RD-Ad4 and Ad7 carrying 
other pathogen genes could be used to make the vaccine even 
more polyvalent.
Even though Ad7 transduction was restored in the CD46+ 
transgenic mice, the vaccine efficacy was actually reduced as 
compared with the BALB/c vaccinated mice. The primary recep-
tor for Ad7 has been described to be Desmoglein 2 (DSG2) 
and mouse DSG2 was found to be refractory to Ad3 transduc-
tion.33 Therefore, the restored transduction in the CD46+ trans-
genic mice may not be representative of Ad7 receptor usage in 
humans. More interestingly, the Ad7 vaccine in the CD46+ mice 
appeared to work equally well or better at lower doses, in con-
trast to the Ad4 vaccine. Also of interest is the fact that Ad4 and 
Ad7 were equally effective at inducing anti-H1NI immunity in 
BALB/c mice when vaccinated intranasally. Since, the imaging 
data indicated that Ad7 did not transduce BALB/c mice very 
efficiently, as compared with Ad4 and Ad5, it is likely that the 
Ad7 vaccine is transducing a smaller subset of cells. This subset of 
cells may be better antigen presenting cells than those transduced 
by the CAR binding Ad4 vaccine. In addition, it is possible that 
the higher levels of Ad7 vaccine in CD46+ mice were inducing 
higher levels of damage to the lungs counteracting the vaccine 
efficacy. Human CD46 is a complement regulatory protein and, 
in the setting of a mouse model, may not accurately represent 
its function in natural immune responses.34,35 It is possible that 
while serving as one of the receptors for Ad7, CD46 may also 
induce immune dysfunction in both Ad4 and Ad7 vaccinated 
mice as indicated by contradictions in our imaging and vaccine 
data. The CD46+ transgenic mice do provide valuable informa-
tion into the complications inherent to small animal models of 
human disease. The fact that increased transgene expression does 
not correlate with increased vaccine efficacy contradicts logical 
vaccine ideology. Recently, a human DSG2 transgenic has been 
established for studying adenoviruses types 3, 7, 11, and 14. As 
DSG2 has been found to be the primary high affinity receptor 
for Ad7 this newly derived mouse model may better serve to eval-
uate human adenoviruses as vaccine vectors.36
Figure 3. Protection by mucosal intranasal immunization in BaLB/c mice. Groups of 5 female BaLB/c mice were immunized intranasally with 10-fold 
serial dilutions of ad4 or ad7 expressing the centralized Ha1-con hemagglutinin gene. Three weeks after immunization the mice were challenged with 
100 MLD50 of mouse-adapted influenza a/PR/8/34. Protection against weight loss and survival induced by the ad4 vaccine is shown in A and B, respec-
tively. Protection against weight loss and survival induced by the ad7 vaccine is shown in C and D, respectively. Mice that lost 25% of baseline body 
weight were humanely euthanized.
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Figure 4. Protection by systemic intramuscular immunization in human cD46+ transgenic mice. Groups of 5 female cD46+ mice were immunized 
intramuscularly with 10-fold serial dilutions of ad4 or ad7 expressing the centralized Ha1-con hemagglutinin gene. Three weeks after immunization the 
mice were challenged with 100 MLD50 of mouse-adapted influenza a/PR/8/34. Protection against weight loss and survival induced by the ad4 vaccine is 
shown in A and B, respectively. Protection against weight loss and survival induced by the ad7 vaccine is shown in C and D, respectively. Mice that lost 
25% of baseline body weight were humanely euthanized.
Figure 5. Protection by mucosal intranasal immunization in human cD46+ transgenic mice. Groups of 5 female cD46+ mice were immunized intrana-
sally with 10-fold serial dilutions of ad4 or ad7 expressing the centralized Ha1-con hemagglutinin gene. Three weeks after immunization the mice were 
challenged with 100 MLD50 of mouse-adapted influenza a/PR/8/34. Protection against weight loss and survival induced by the ad4 vaccine is shown 
in A and B, respectively. Protection against weight loss and survival induced by the ad7 vaccine is shown in C and D, respectively. Mice that lost 25% of 
baseline body weight were humanely euthanized.
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While our data indicate that Ad4 and Ad7 may be suitable 
vaccine vectors for translation to human use, there were several 
limitations involved with our in vitro analyses. Our Ad4 vac-
cine, when delivered intramuscularly, induced 100% survival in 
mice against a lethal heterologous influenza challenge at a dose 
of 109 vp/mouse. The human vaccine dose (~105 infectious units) 
used to provide protection against Ad4 and Ad7 ARD is small 
compared with the dose required to protect mice from influenza 
infection.37 The differences in the vaccine doses needed to protect 
against influenza virus and Ad-ARD can be explained by fun-
damental differences in the viruses and associated disease. First, 
adenoviral genomes are very stable and have an extremely low 
mutation rate as compared with influenza virus.38 The stability 
of the adenovirus genome ensures that the challenges are always 
homologous. This is not the case for influenza virus and is the 
central idea behind the use of a centralized HA gene as a broadly 
reactive influenza vaccine. In this study the influenza challenge 
is heterologous and the degree of mismatch between the vaccine 
HA and the challenge flu HA is 8.5%. In this light, we feel that 
our data indicate that protection against endemic or even pan-
demic influenza, would be achieved at much lower doses of vac-
cine, especially in the case of a homologous matched challenge 
influenza. Second, vaccinated mice are challenged with a dose of 
100 MLD
50
 of mouse-adapted influenza virus whereas Ad-ARD 
infections are generally not lethal The only measure of vaccine 
efficacy in this study was a lethal influenza challenge. A signifi-
cant shortcoming is the lack of hemagglutination inhibition or 
influenza virus neutralization data. These immune correlates 
would provide valuable insight into the degree and breadth of the 
induced immune responses and will be included in future stud-
ies. Although we did not do any in vitro anti-influenza analyses a 
previous study evaluated the centralized HA1-con gene to induce 
protection against 2009 pandemic swine flu in vivo. When vac-
cines were mismatched the centralized HA1-con gene was a bet-
ter vaccine gene as compared with wildtype heterologous HA 
genes.11
In 2010, 1.24 million people, mostly children, died from 
malaria worldwide.39 Malaria infections remain a significant 
health hazard to our military personnel.40,41 In a recent study by the 
US Military Malaria Vaccine Program, vaccination using a DNA 
prime and Ad5 boost expressing circumsporozoite protein (CSP) 
and apical membrane antigen-1 (AMA1) from Plasmodium falci-
parum protected 27% of vaccinees against a live malaria challenge. 
All of the vaccinees that had moderate to high titers of anti-Ad5 
pre-existing immunity were susceptible to malaria infection.42 The 
authors suggest that the use of alternative lower seroprevalent Ad 
vectors and the inclusion of a third antigen should be considered a 
priority for future studies. While Ad4 and Ad7 have been shown 
to have moderate levels of pre-existing immunity, it is estimated 
that nearly 90% of unimmunized US Army trainees would be sus-
ceptible to at least 1 of these Ad types. Studies have shown that 
pre-existing immunity to Ad5 is as high as 70% in the USA and 
90–100% in Asia and Africa, the prime sites for the implementa-
tion of a malaria vaccine.14,16,43 We speculate that recombinant Ad4 
and Ad7 expressing P. falciparum genes may be optimal Ad vec-
tors to create a multivalent malaria vaccine. We feel that this data 




Female, 6–8-wk-old, BALB/c mice were obtained from 
Charles River. Human CD46+ transgenic mice on a C57/
BL6 genetic background were obtained from the Mayo Clinic 
toxicology core and a breeding colony was established under 
the IACUC, protocol A61312. Mice were housed in the Mayo 
Clinic Animal Facility under the Association for Assessment and 
Accreditation of Laboratory Animal Care (AALAC) guidelines 
with animal use protocols approved by the Mayo Clinic Animal 
Use and Care Committee, protocol A24111). All animal experi-
ments were performed according to the provisions of the Animal 
Welfare Act, PHS Animal Welfare Policy, the principles of the 
NIH Guide for the Care and Use of Laboratory Animals, and the 
policies and procedures of Mayo Clinic.
Virus and DNA purification
Adenovirus type 4 strain RI-67 (ATCC VR-1572) and type 
7 strain Gomen (ATCC VR-7) were purchased from ATCC. 
The Ad4 and Ad7 strains were obtained from throat swabs of 
California military recruits with pharyngitis in 1954.44 Final 
amplification of the virus was performed in a Corning 10-cell 
stack (~6300 cm2). Virus was amplified in 293 cells and purified 
on 2 sequential CsCl ultracentrifuge gradients. Purified viruses 
were quantitated by OD260. Viral genomic DNA (gDNA) was 
purified using high-titer Ad4 and Ad7 purified virus and the 
PureLink Viral RNA/DNA mini kit (Invitrogen).
Cloning of the Ad4 and Ad7 Genomes
An overlapping PCR product was amplified in order to clone 
the Ad4 gDNA by homologous recombination. First, the left 
and right arms of the Ad4 gDNA were amplified by PCR using 
Platinum Taq Supermix High Fidelity (Invitrogen) (Fig. 6A). 
Unique PacI restriction enzyme site were added just outside 
of the left and right ITRs. The primers were designed to over-
lap and contained a unique NdeI site in between the left and 
right arms of the genome (Fig. 6A). Table 1 shows the primers 
used to clone the Ad4 gDNA. The Ad4-PacI-ITR acts as both 
a forward and reverse primer since the sequence is an inverted 
repeat. All PCR reactions were performed using Platinum Taq 
Supermix High Fidelity (Invitrogen). In order to amplify the left 
arm of Ad4, primers Ad4-PacI-ITR and Ad4-Recomb-R (200 
mM final) were combined with 0.5 µg of Ad4 gDNA in 45 µl 
of Platinum Supermix. In order to amplify the right arm of Ad4, 
primers Ad4-PacI-ITR and Ad4-Recomb-F (200 mM final) 
were combined with 0.5 µg of Ad7 gDNA in 45 µl of Platinum 
Supermix. The following parameters were used for PCR: 95 °C 
(2 min); 20 cycles of 95 °C (30s): 55 °C (30s): 68 °C (3.5 min); 
68 °C (10 min); 4 °C (∞). One microliter of each PCR reaction 
was combined in 45 µl of Platinum Supermix and the primer 
Ad4-PacI-ITR was added to a final concentration of 400 mM. 
The following parameters were used for PCR: 95 °C (2 min); 
20 cycles of 95 °C (30s): 55 °C (30s): 68 °C (3.5 min); 68 °C 
(10 min); 4 °C (∞). The overlapping PCR product was cloned 
550 Human Vaccines & Immunotherapeutics Volume 10 Issue 3
Figure 6. see page 551 for legend. 
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Table 1. Primers for cloning ad4 and ad7 gDNa
ad4-PacI-ITR TTaaTTaacT aTcTaTaTaa TaTaccTTa TTTTT
ad4-Recomb-F caGTcaTaTG cTGGccGccG TGcaTGGTca ccTcTcaacG acTTTcaaaT Tcc
ad4-Recomb-R GGaaTTTGaa aGTcGTTGaG aGGTGaccaT GcacGGcGGc caGcaTaTGa cTG
Kan ori PacI-F TTaaTTaacG GTGTGaaaTa ccGcacaGaT GcG
Kan ori PacI-R TTaaTTaaGa aTTaaTTcGa TccTGaaTGG cG
ad7-asisI-ITR aaGcGaTcGc cTaTcTaTaT aaTaTaccTT aTaGaTGG
ad7-Recomb-F GaGGccacTc TTGaGTGcca GcGaGGTTTa aacGcGGaTa caaaGTaaaa GGcacaGGaG
ad7-Recomb-R cTccTGTGcc TTTTacTTTG TaTccGcGTT TaaaccTcGc TGGcacTcaa GaGTGGccTc
Kan ori asisI-F GcGaTcGcTa aTTaacaTGc aTGGaTccaT aTGcGGTGTG
Kan ori asisI-R GcGaTcGcTT aaTTaaGaaT TaaTTcGaTc cTGaaTGGcG aaTGG
Figure 6 (See previous page). schematic of ad4 gDNa cloning. The right and left arms of ad4 were amplified with primers designed to incorporate 
a unique NdeI restriction site, an overlap of ~27 nucleotides and flanking PacI restriction sites (A). The 2 PcR products were fused together in a second 
round of amplification (B). a schematic representation of the cloning fragment is shown (C). The cloning PcR fragment is ligated to the Kanamycin resis-
tance gene and the pBR322 origin of replication (D). The recomb cloner plasmid was digested with NdeI and recombined with the ad4 genomic DNa in 
vitro using BJ5183 electrocompetent cells (E). The complete ad4 genomic DNa plasmid is shown (F).
into TOPO pCR8 (Invitrogen) and confirmed by sequencing 
(Fig. One B and C). The Kanamycin resistance gene (KANR) and 
the pBR322 origin of replication (pBR322 ori) from pAd-Shuttle 
(Stratagene) was amplified using the primers Kan ori PacI-F and 
Kan ori PacI-R and the PCR product was cloned into TOPO-XL 
(Invitrogen) (Table 1). The KanR and pBR322 ori were ligated to 
the overlapping PCR using the PacI sites to form the cloning plas-
mid, pAd4-recomb-cloner (Fig. 6D). The pAd4-recomb-cloner 
plasmid was digested overnight with NdeI and dephosphorylated 
with Antarctic Alkaline Phosphatase (New England Biolabs). 
Digested cloner plasmid and 1.0 μg of purified Ad4 gDNA were 
cotransformed into BJ5183 electrocompetent cells, incubated at 37 
°C with shaking for 1 h and plated on LB Kanamycin (Fig. 6E). 
The plates were incubated at 37 °C overnight and small pinpoint 
colonies were picked for minipreps. The miniprep DNA was con-
firmed by restriction enzyme digestion and transformed into XL-1 
blue electrocompetent cells. The DNA was maxiprepped using 
Qiagen HI Speed Maxi kits. The Ad7 genome was cloned in a sim-
ilar manner with the exception that AsiSI unique restriction sites 
flanked the Kanr and pBR322 oriP regions and the pAd7 recomb 
cloner plasmid was linearized with PmeI (Fig. 7).
The pAd4 and pAd7 complete genome plasmid (pAd4-com-
plete and pAd7-complete gDNA Final, respectively) were con-
firmed by restriction enzyme analyses (Fig. 6F and Figure 7F). 
In order to confirm that the plasmids contained functional viral 
gDNA, the PacI, and AsiSI digested pAd4 and pAd7 plasmids 
were transfected into 293 cells using Polyfect (Qiagen) and wt 
Ad4 and Ad7 virus was confirmed by plaque formation and virus 
amplification.
Construction of shuttle plasmids
A series of shuttle plasmids were constructed in order to create 
the Ad4 and Ad7 E3 modified viruses. Table 2 shows the prim-
ers used to create the shuttle plasmids. Each shuttle was created 
using an overlapping PCR product that contained a unique AscI 
restriction enzyme site (Fig. 8A). The overlapping PCR products 
were amplified as previously described. The Ad4 and Ad7 E3 
shuttle PCR products contained flanking PacI restriction sites. 
The final PCR products were cloned into the TOPO pCR8 clon-
ing vector (Invitrogen, Carlsbad). Each shuttle was confirmed by 
sequencing.
The HA1-con and GFPLuc genes were cloned into the strata-
gene pShuttle-CMV plasmid (Startagene). The CMV-HA1-con-
PolyA and CMV-GFPLuc-PolyA expression cassettes were fused 
to the FRT-Zeocin-FRT sequence by overlapping PCR. Table 3 
shows the primers used to create the final PCR products. AscI 
restriction sites were incorporated into the PCR primers for liga-
tion into the shuttle plasmids. Both PCR amplified transgenes 
were cloned into TOPO pCR8 (Invitrogen) and confirmed by 
sequencing. Schematic representations of the 2 transgene cas-
settes are shown in Figure 8B.
The final shuttle plasmids were created by digesting the shut-
tle plasmids with AscI and dephosphorylating with Antarctic 
alkaline phosphatase. The HA1-con-FZF and GFPLuc-FZF 
plasmids were also digested with AscI and the plasmid backbone 
was cut with MluI. The digested plasmids were ligated with T4 
DNA ligase and transformed into XL-1 electrocompetent cells.
To make the recombinant Ad4 and Ad7 plasmids, the shuttle 
plasmids were digested with PacI, buffer exchanged, and cotrans-
formed with 1.0 µg of pAd4 or pAd7 in BJ5183 electrocompetent 
cells. Recombinants were selected on LB containing Kanamycin 
and Zeocin. Recombinants were confirmed by restriction diges-
tion analysis. Positive recombinant clones were transformed into 
XL-1 cells and maxiprepped using the Qiagen HI Speed Maxi 
kits (Qiagen).
Recombinant Ad4 and Ad7 rescue and purification
The recombinant Ad4 and Ad7 genomes were released from 
the plasmid backbone by digestion with PacI and AsiSI, respec-
tively. The digested plasmids were buffer exchanged using a 
Strataprep PCR purification kit (Agilent Technologies). All 
transfections were performed in 6-well plates as described by 
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Figure 7. see page 553 for legend. 
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Polyfect Transfection reagent (Qiagen). Viruses were released 
from infected cells by 3 freeze-thaw cycles and amplified in 
sequential passages in the complementing host cell lines. The 
viruses were amplified and purified as previously described for 
wt Ad4 and Ad7. All viral preps were quantitated by OD260. 
Infectious units of Ad4 and Ad7 expressing GFPLuc were deter-
mined by infecting 293 cells and quantitated by direct observa-
tion usning fluorescent microscopy.
In vivo luciferase activity
Luciferase activity induced by the Ad4 and Ad7 GFPLuc 
expressing viruses was determined using a Lumazone imaging 
system (Roper Scientific). Female BALB/c and CD46+ trans-
genic mice were anesthetized using ketamine/xylazine and 1010 
vp of each virus was injected intramuscularly using a 27 gauge 
needle into both quadriceps in 2, 25 µl injections. For intra-
nasal immunization, the mice were anesthetized and placed on 
their back. Virus was pipetted into the nares in 2 10 microliter 
instillations. Twenty-four hr. post-immunization, the mice were 
anasthesized with ketamine/xylazine and injected intraperitoneal 
with 200 μl of d-luciferin at a concentration of 20 mg/ml in PBS. 
The hair on the CD46+ transgenic mice was removed using a 
Wahl trimmer in order to improve luciferase detection. The mice 
were immediately placed into the Lumazone Imager and images 
were captured. All images were taken with a 10 min exposure 
and 4 × 4 binning using no filters and no photo-multiplication. 
Data analysis was performed on each image using background 
subtracted sum intensities as detected by the Lumazone Imaging 
Software and graphed using PrismGraphing Software.
Immunizations and influenza challenge
Protection against influenza challenge by the HA1-con 
expressing Ad4 and Ad7 vaccines was determined by serial dilu-
tion of the vaccine in BALB/c and CD46+ transgenic mice. All 
immunizations and challenges were performed using ketamine/
xylazine anesthetized mice as previously described. Intranasal 
and intramuscular immunizations were performed as previously 
described for in vivo luciferase activity. Mice were immunized 
with 10-fold dilutions of the vaccine vectors from 1010 to 107 vp/
mouse. Three weeks after immunization the mice were challenged 
with 100 MLD
50
 of mouse-adapted A/PR/8/34 influenza virus 
as previously described.11 The mice were observed for 2 wk for 
signs of disease, weight loss, and death. Mice that lost more than 
25% of baseline body weight were humanely euthanized.
Ad neutralization assay
Ad7 neutralization was performed as previously described.45 
Briefly, serial dilutions of plasma were made in cDMEM and 
incubated in triplicate for 1 h at 37 °C with 500 vp of Ad7 vector 
expressing the eGFP-luciferase fusion gene. The resulting solu-
tion was added to A549 cells in a black 96 well plate for 24 h and 
luciferase activity was measured. Data are expressed as the mean 
titer that reduced Ad7 luciferase activity by ≥90%.
In vitro luciferase activity
293 cells were infected with 104 vp/cell of either Ad4 or 
Ad7 virus expressing the GFPLuc gene. The luciferase activity 
was determined 24 h post-infection by lysing the cells with the 
reporter lysis 5X buffer. Luciferase activity was detected using 
the luciferase assay reagent (LAR) (Promega) as described by the 
manufacturer protocol. Briefly, 25 µl of 5X lysis buffer was added 
to each well of a 96-well plate and mixed. Then 50 µl of LAR was 
added and the luciferase activity was measured using a Beckman 
Coulter DTX 880 microplate reader.
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Figure 7 (See previous page). schematic of ad7 gDNa cloning. The right and left arms of ad7 were amplified with primers designed to incorporate a 
unique PmeI restriction site, an overlap of ~27 nucleotides and flanking asisI restriction sites (A). The 2 PcR products were fused together in a second 
round of amplification (B). a schematic representation of the cloning fragment is shown (C). The cloning PcR fragment is ligated to the Kanamycin resis-
tance gene and the pBR322 origin of replication (D). The recomb cloner plasmid was digested and recombined with the ad7 genomic DNa in vitro using 
BJ5183 electrocompetent cells (E). The complete ad7 genomic DNa plasmid is shown (F).
Table 2. Primers for ad4 and ad7 shuttle Plasmids
ad4-Δe3-F TTaaTTaacT GacTTTGGaG aGTTcTTccT cGc
ad4-Δe3-OL-R GTaaTGGGGT aaGGGGTTaG TTGaTGGcGc GccTcaGcTT TTaTTaTacT caGTac
ad4-Δe3-OL-F GTacTGaGTa TaaTaaaaGc TGaGGcGcGc caTcaacTaa ccccTTaccc caTTac
ad4-Δe3-R TTaaTTaaTG caaTGaGTTT TcccGaGTcG TcaaG
ad7-Δe3-F TTaaTTaacc TaTGTcGTca ccGaccTcaa caG
ad7-Δe3-OL-R caaGTaaGTG aTTTTTTaTT aaTTTTGGcG cGccGaTGGT aaTccGcacT ccGTGGGc
ad7-Δe3-OL-F GcccacGGaG TGcGGaTTac caTcGGcGcG ccaaaaTTaa TaaaaaaTca cTTacTTG
ad7-Δe3-R TTaaTTaaGG GTccTaGcGa caaaccTaTa GaG
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Figure 8. construction of e3 shuttle plasmids and transgenes. In order to create replication-competent vectors, the nonessential e3 were genes replaced 
with either a Ha1-con expression cassette or a GFPLuc fusion gene. The PcR products that were used to create the shuttle plasmids for ad4 and ad7 
are shown (A). Both of the overlapping PcR products were designed to flank the e3 genes and contained unique ascI sites. The ascI flanked transgene 
expression cassettes are shown (B). The cMV expression cassettes were fused to a FRT flanked zeocin gene for selection of recombinants and ultimate 
removal by FLP recombinase.
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Table 3. Primers for Transgenes
cMV-ascI-F GGcGcGcccG cGTTacaTaa cTTacGGTaa aTGGcc
ad-GL-FZF-R GcTaGcGaTa TcGcGGccGc GaGcTcaTaa GaTacaTTGa TGaGTTTGGa caaaccacaa cTaGaaTGca GTG
ad-GL-FZF-F cacTGcaTTc TaGTTGTGGT TTGTccaaac TcaTcaaTGT aTcTTaTGaG cTcGcGGccG cGaTaTcGcT aGc
FZF-ascI-R GGcGcGccGa TccGcGTTGc cTGcaGGTcG acTcTa
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Supplemental Figure 1.  In vitro luciferase activity and infectious units of 
Ad4 and Ad7 viruses.  In order to determine if both Ad vaccines were capable 
of expressing equivalent levels of transgene protein we measure luciferase 
activity in Ad4 and Ad7 virus infected 293 cells (A).  In order to determine the 
virus particle to infectious unit ratios, the Ad4 and Ad7 virus transduction of 293 
cells in vitro was determined.   293 cells were incubated with the viruses 
expressing GFPLuc and quantitated by direct visualization using fluorescent 
microscopy (B).  Error bars indicate standard deviation. 
 
Supplemental Figure 2.  Ad7 in vivo induced neutralization.  BALB/s mice 
were immunized with 1010 vp/mouse of Ad7 expressing GFPLuc.  Sera was 
collected on day 21 post-immunization and Ad7 neutralizing antibodies were 
measured.  The mean titer that inhibited 90% of Ad7 luciferase expression is 
shown.  Error bars indicate standard deviation (n = 5).	  
